SELECTED FORESIGHT SEMINARS

DRA Foresight Briefing: The Social Determinants of Health, and Health in All Policies (10/20/2009)

Congresswoman Donna M. Christensen, Delegate from the United States Virgin Islands, House of Representatives
Larry Cohen, Executive Director, Prevention Institute
Brian D. Smedley, Ph.D., Vice President & Director, Health Policy Institute Joint Center for Political and Economic Studies
Adolph P. Falcón, MPP, Senior Vice President, National Alliance for Hispanic Health
summary | handouts and presentations

DRA Foresight Briefing: Health Equity: Focusing on Health in All Policies (02/25/2009)

Congresswoman Donna M. Christensen, Delegate from the United States Virgin Islands, House of Representatives
Brian D. Smedley, Ph.D., Vice President & Director, Health Policy Institute Joint Center for Political and Economic Studies
David R. Williams, Ph.D., Florence & Laura Norman Professor of Public Health Harvard School of Public Health and Staff Director, Robert Wood Johnson Foundation Commission to Build a Healthier America
Dolores Acevedo‐Garcia, Ph.D., Associate Professor of Society, Human Development and Health, Harvard School of Public Health
Larry Cohen, MSW, Executive Director, Prevention Institute
summary | handouts and presentations

DRA Foresight Briefing: The Health Disparities Collaboratives - Enhancing Quality and Reducing Disparities (11/24/2008)

David M. Stevens, MD, Associate Medical Director & Director Quality Center, National Association of Community Health Center, Research Professor, Department of Health Policy at George Washington School of Public Health and Health Services
Paloma Hernandez, President & CEO, Urban Health Plan
Roland Gardner, Chief Executive Officer, Beaufort, Jasper, Hampton Comprehensive Health Services, Inc.
handouts and presentations

DRA Foresight Briefing: Reducing Health Disparities Faster - Addressing Social Determinants of Health (12/06/2007)

Larry Cohen, MSW, Executive Director, Prevention Institute
Dolores Acevedo‐Garcia, PhD, Associate Professor of Society, Human Development, and Health, Harvard School of Public Health
Stephen Thomas, PhD, Director of the Center for Minority Health at the University of Pittsburgh Graduate School of Public Health and Philip Hallen Professor of Community Health & Social Justice
Amparo Castillo, MD, MS, Project Director, Midwest Latino Health Research, Training & Policy Center, University of Illinois Chicago
Rosemarie M. Henson, MPH, MSSW, Deputy Director, National Center for Chronic Disease Prevention and Health Promotion, CDC
webcast | handouts and presentations

The Looming Diabetes Crisis: Can it be Prevented? (06/23/2006)

Tom Boyer, Executive Director of Diabetes Care Coalition
Dr. Francine Kaufman, one of the nation’s foremost pediatric endocrinologists and professor of pediatrics at the Keck School of Medicine of the University of Southern California and Children’s Hospital Los Angeles
R. Stewart Perry, Vice Chair of National Board of Directors of the American Diabetes Association
Dr. William Rowley, Senior Futurist and Chief Operating Officer for the Institute for Alternative Futures
summary

Evolving Payments for Improved Care (12/16/2003)

Gerard Anderson, Robert Wood Johnson Foundation
Dr. Timothy Ferris, Partners/ MGH Institute for Health Policy
Judith Hibbard, University of Oregon
summary

Rethinking Payment Systems for the Future (10/30/2003)

Richard Sorian, National Committee for Quality Assurance (NCQA)
Stuart Guterman, Centers for Medicare and Medicaid Services (CMS)

The Next Wave of Healthcare Reform (06/06/2003)

Dr. Glenna Crooks, Strategic Health Policy International. Inc
Dr. William Rowley, Institute for Alternative Futures
Dr. Gail Warden, Henry Ford Health System
full report | summary

Misconceptions & Potential from the Human Genome (01/24/2003)

Dr. Alan Guttmacher, National Human Genome Research Institute
Dr. Allen David Roses, Genetics Research, GlaxoSmithKline
Dr. Christopher Webster, Millennium Pharmaceuticals
Dr. Robert Wells, Affymetrix, Inc
summary

Bioterrorism: Leveraging Science & Policy Approaches (10/25/2002)

Susan Neely, Office of Homeland Security
Dr. Kenneth Alibek, George Mason University
Dr. Michael Osterholm, University of Minnesota
summary

Medicare Futures: Generational Perspectives & New Medical Technologies (05/31/2002)

Neil Howe, Author and National Speaker
Dr. Joshua Cohen, Tufts Center for the Study of Drug Development
full report | summary

New Threats: Infectious Diseases and Drug Resistant Pathogens (02/26/1999)

Dr. Sue Binder, Centers for Disease Control and Prevention (CDC)
Dr. Claire M. Fraser, The Institute for Genomic Research (TIGR)
Dr. Glenn Tillotson, Bayer

Policy Implications of Complementary and Alternative Therapies (02/09/1999)

Brian Berman, MD, University of Maryland
Louis Sportelli, DC, Triad Healthcare Inc.
John Weeks, The Integrator

Balancing The Future With The Present: Foresight For Drug Price Competition and Patent Term Restoration (11/12/1998)

Bruce Downey, Barr Laboratories
Kay Holcombe, Policy Directions Inc.
Jeffrey Stritar, Pfizer

From Hindsight to Foresight: Lessons Learned from Waxman-Hatch 1984-1998 (06/05/1998)

W. Douglas Campbell, Fleishman Hillard
Steven A. Grossman, Hill and Knowlton

Information Solutions for Health Systems Management (03/13/1998)

Senator Conrad Burns, (R) Montana
Col. Gail Maestas, Triservice Corporate Executive Information Systems (DoD)
Phil Newbold, Health Care Technologies, SAIC
Dr. Don Lindberg, National Library of Medicine

Aging Ain’t What It Use to Be: The Demographic Challenge to Medicare and other Government Policies (12/05/1997)

Robert Blancato, Matz, Shea, Blancato, Public and Government Relations
S. Jay Olshansky, Ph.D., University of Chicago
Deborah Steelman, Law Offices of Deborah Steelman

Medicaid, Managed Care and Prevention: Insights for Success (11/07/1997)

Eric Baumgartner, M.D., MPH, Texas Department of Health
Janet Shikles, Powers, Pyles, Sutter & Verville
Michael Nolin, Deputy Director, Managed Care Programs, University of Maryland Baltimore County

The Future of Health Quality and Outcomes (10/10/1997)

Roger Evans, Ph.D., Mayo Clinic
James Fries, MD, Stanford University School of Medicine
William Golden, MD, Center for Clinical Quality Evaluation (CCQE)

Clinical Development in the 21st Century (07/18/1997)

Michael Hurley, M.S., JD, MBA, Director, Venture Consulting, Abbott Laboratories
Judith Jones, MD, Ph.D., President, The Degge Group
Carl Peck, MD, Professor of Pharmacology & Medicine, Georgetown University
Theodore Pincus, MD, Professor of Medicine, Vanderbilt University
William Wardell, MD, Senior Scientific Officer, Covance Clinical and Periapproval Services
summary

Information, Privacy and Health in the Networked World (06/06/1997)

Heider Wagner Hayduk, Esq., Health Care Leadership Council
Andrew S. Ripps, Director, Professional & Government Affairs, Healthpoint
Lucian Russell, Ph.D., Argonne National Laboratory
Peter Tippett, M.D. Ph.D., National Computer Security Association

What’s News with Ewe: Cloning, Medical Science and Health Implications (05/09/1997)

Julian Cooper, Ph.D., President, PPL Therapeutics
Jim Robl, Ph.D., President, Advanced Cell Technology, Professor, University of Massachusetts
Walter Truett-Anderson, Vice President, Meridian Institute
Gladys White, Ph.D., Director, National Advisory Board on Ethics and Reproduction (NABER)
summary

Issues from the Future: Health by Design or Default (12/10/1996)

Clement Bezold, Ph.D., President, Institute for Alternative Futures
Linda Harris, Ph.D., Director Health Care Systems, Concept Five Technologies
Robert Olson, Research Director, Institute for Alternative Futures
Jonathan Peck, Vice President, Institute for Alternative Futures
transcript

Innovations in Pharmaceutical Science: Breakthroughs in Neuroscience (10/25/1996)

Frederick Goodwin, M.D., Center on Neuroscience, George Washington University
Peter Whitehouse, M.D., Ph.D., Alzheimer’s Research Center, Case Western Reserve University
Eric Zillmer, Ph.D., Department of Psychology, Drexel University
Pat Levitt, Ph.D., Department of Neurobiology, University of Pittsburgh School of Medicine
transcript

Patient Rights and Advocacy Organizations in the 21st Century (09/20/1996)

Mary Jo Deering, Ph.D., Director, Health Communication and Telehealth Staff, Office of Disease Prevention and Health Promotion, DHHS
Robert Goldberg, MHS, Director of Membership Services, National Health Council
Joseph Henderson, M.D., Dartmouth Medical School
Stephen Lamb, Assistant Vice President for Public Policy, National Committee for Quality Assurance
Molly Mettler, MSW, Project Director, Healthwise Communities Project, Healthwise Inc.

Health and the Information Superhighway (07/26/1996)

Thomas Tinstman, M.D., Senior Vice President, Cerner Corporation
Robert Bruegel, Ph.D., Clinical Reference Systems Ltd. (CRS)
Hugh Brownstone, Vice President, Strategic Business Development, IMS America (IMSA)
Jonathan Peck, Managing Director, Institute for Alternative Futures

The Future of International Pharmaceutical Markets (06/21/1996)

Harvey Bale, Jr., Ph.D., Senior Vice President, International Affairs, PhRMA
Tim Sayles, Pharm.D., Ciba-Geigy Corporation
Jonathan Peck, Managing Director, Institute for Alternative Futures

The Future of Product Regulation (05/17/1996)

Ellen C. Cooper, M.D., Vice President and Director of the Department of Clinical Research and Information for the American Foundation for AIDS Research (AmFAR)
Kenneth Kaitin, Ph.D., Associate Director, Tufts Center for the Study of Drug Development, Tufts University
Marguerite Donoghue, R.N., M.S.N., Co-Director, FDA Council
Jonathan Peck, Managing Director, Institute for Alternative Futures

Frontiers in Pharmaceutical Innovation (12/01/1995)

Dr. Lloyd M. Smith, Professor of Chemistry at the University of Wisconsin at Madison
Dr. Leslie Benet, Professor and Chairman of the Department of Pharmacy at the University of California, San Francisco and founder and Chairman of the Board for AvMax, Inc.
Dr. Ronald T. Borchardt, Professor and Chairman of Department of Pharmaceutical Chemistry at the University of Kansas
transcript

The Third-Wave Marketplace and the Future of Medicaid and Medicare (11/17/1995)

Mary Kennesson, Senior Associate with Pacific Health Policy Group
Paul Rothman, Executive Director of Frontier Health Services of Miami, Florida
Leonard Kirschner, Vice President for Health Care Initiatives for EDS

The Pharmaceutical Marketplace (09/28/1995)

Leslie G. Epstein, P.D., Vice President of Managed Care Relations for Advance ParadigM, Inc.
John A. Gans, Pharm.D., Executive Vice President and CEO of the American Pharmaceutical Association (APhA)
Robert N. Merold, Vice President of Marketing and Business Development for IMS America, a Dun & Bradstreet Company
Ronald J. Streck, President and CEO of the National Wholesale Druggists’ Association (NWDA)

Vision and FDA Reform (08/21/1995)

An invitational workshop
transcript

Human Genome Project: Implications for the Future of Biotechnology (12/02/1994)

Dr. Marty Rosenberg, Senior Vice President, Biopharmaceutical R&D SmithKline Beecham Pharmaceuticals
Dr. Paula Gregory, Chief, Genetics Education Program National Center for Human Genome Research, NIH
transcript

Innovation and Regulation: Models for Reengineering (11/10/1994)

Peter Bewley, NovaCare, Inc.
Douglas Michael, University of Kentucky School of Law
transcript

Innovation in Care Delivery: Disease Management Systems (10/07/1994)

Sandra Kretz, Quantum Health Resources, Inc.
Douglas Stickney, Quantum Health Resources, Inc.
Roman Yanda, USC School of Medicine

Health Reform and the Future of Innovation (06/09/1994)

Rebecca Henderson, MIT Sloan School
Steven Wheelwright, Harvard University
transcript

Safety, Efficacy and Cost Effectiveness: Policies for the 21st Century (02/16/1994)

Louis Lasagna, M.D., Center for the Study of Drug Development
Bryan Luce, Ph.D., M.B.A., Battelle Medical Technology and Policy Research Center
Robert Temple, M.D., Food and Drug Administration
Ann Witt, Food and Drug Administration

Technology Assessment for Pharmaceuticals in Health Care Reform (12/10/1993)

Harold J. DeMonaco, Massachusetts General Hospital
Wayne A. Ray, Vanderbilt University
Thomas V. Holohan, Agency for Health Care Policy Research (AHCPR)

Incentives for Prevention in Health Care Reform (12/03/1993)

Halley Faust, M.D., MPH, Medmax Services, Inc.
William Harlan, M.D., Office of Disease Prevention, NIH
John Siegfried, M.D., Pharmaceutical Manufacturers Association

A Universal Drug Benefit (11/01/1993)

Jerry Avorn, Harvard Medical School
Howard Cohen, House Energy & Commerce Committee
John Coster, Senate Special Committee on Aging
Scott Harrison, Congressional Budget Office
Roy Ramthun, Senate Finance Committee
Louise Rodrigues, Department of Veterans Affairs
David Schulke, Representative Wyden
Bill Schultz, House Energy & Commerce Committee

Pharmaceutical Marketing During the Information Revolution (09/24/1993)

Clement Bezold, Ph.D., Institute for Alternative Futures
Kenneth Cohen, National Pharmaceutical Council
William Tierney, Regenstrief Institute for Health Care, Indiana University School of Medicine

The Price of Future Medicines (07/23/1993)

Susan Blumenthal, M.D., M.P.A., Chief, Behavioral Medicine, National Institute of Mental Health
Rick Carlson, J.D., Author and Consultant
James Gordon, M.D., Director, The Center for Mind-Body Studies
Thomas Pyle, Senior Advisor, The Boston Consulting Group
Richard Studer, President, Consumer Perception Strategies, Inc.

Future Medicines and National Health Reform (06/11/1993)

Gene Cohen, National Institute on Aging
Joe Jacobs, NIH, Office of Alternative Medicine
Jack Killen, NIAID
John Weeks, American Association of Naturopathic Physicians
Mark Zukowski, Amgen

Health Care Reform and Access to Pharmaceuticals (12/21/1992)

Clement Bezold, Ph.D., Executive Director, Institute for Alternative Futures
Dan Durham, Legislative Representative, American Association of Retired Persons
Lynn Etheredge, Health Care Consultant
Donald Lee, Vice President, Professional Affairs, Procter & Gamble
Lawrence Lewin, Chairman, Lewin ICF Health and Income Group
Barbara Redman, Executive Director, American Nursing Association

Pharmaceutical Research and Special Populations (12/14/1992)

Lionel Edwards, M.D., Assistant Vice President and Senior Director, International Clinical Research, Hoffmann- La Roche
Barry Gurland, M.D. , Director, Columbia University Center for Geriatrics and John E. Borne Professor of Clinical Psychiatry
Marianne J. Legatto, M.D., Associate Professor of Clinical Medicine, Columbia University of Physicians and Surgeons; and director of Post Graduate Medical Education, St. Luke’s-Roosevelt Institute for Health Sciences
Theresa Radebaugh, S.c.D., Chief, Dementias of Aging Branch, Neuroscience and neuropsychology of Aging Program, National Institute on Aging
Stephen Spielberg, M.D., Ph.D., Executive Director, Exploratory Biochemical Toxicology, Merck, Sharpe & Dohme

International Markets and Pharmaceutical Prices (11/09/1992)

Fredrik Andersson, Ph.D., Research Scientist, Battelle’s Medical Technology and Policy Center in London; authored numerous reports on international comparisons of health care expenditures
Jonathan Ratner, Ph.D., Assistant Director for Medicare and Medicaid issues at U.S. General Accounting Office; taught economics at Wellesley College and at SUNY-Albany

The Future of Pharmaceutical Pricing (09/21/1992)

Mick Kolassa, Research Associate, University of Mississippi Research Institute of Pharmaceutical Sciences Health Services Research Division
Steven W. Schondelmeyer, Ph.D., Professor, College of Pharmacy, University of Minnesota College of Pharmacy; holds the nation’s first Endowed Chair in Pharmaceutical Management and Economics

Managed Care and the Pharmaceutical Industry (08/20/1992)

Janet Corrigan, National Committee for Quality Assurance
Dennis Longstreet, Ortho Biotech Inc.
David McLean, Clinical Pharmacy Advantage
David Miller, Maryland Pharmacist Association
Ed Moy, Health Care Finance Administration
Jeff Sanders, Health Care Finance Administration
Eleanor Socholitzky, Blue Cross & Blue Shield Massachusetts
William Tindall, Academy of Managed Care Pharmacy

Drug Utilization Review: Beyond the Next Phase (07/06/1992)

Bill Abrams, M.D., Merck Research Labs
Gary Erwin, Pharm.D., Philadelphia College of Pharmacy
Steve Mullenix, R. Ph., Q A, Inc.
Jan Brandenburg, First Virginia Health Services
Tom Fulda, Health Care Financing Adm.
Jeff Sanders, Health Care Financing
Jerry Brager, American Medical Assoc.
Edward Lennard, Pharm.D., Health Information Designs
Jerome Seidenfield, Ph.D., American Medical Assoc.
Tricia Byrns, M.D., University of Colorado
Aida LeRoy, Pharm.D., PharMark, Corp.
James Smith, Ameritech
Ted Collins, Ctr. for Health Systems Research and Analysis
M. Lee Morse, PharMark Corp.
Tom Snedden, PACE

Prescribing Pharmaceuticals for Uses not Approved by the FDA (11/19/1991)

Joseph S. Bailes, M.D., Chairman, Clinical Practice Committee, American Society of Clinical Oncology and board-certified oncologist; and Clinical Assistant Professor, University of Texas Health Science Center at San Antonio
Kenneth W. Johnson, Director, Drug Information Division, United States Pharmacopeial Convention, Inc.
Joel E. Miller, Director, Professional Services for the Health Association of America

Drug Approvals in the U.S. and Abroad (10/07/1991)

D. Bruce Burlington, M.D., Deputy Director, Scientific and Medical Affairs, and Deputy Director of the Office of Drug Evaluation II at the FDA
Brenton E. James, Senior Regulatory Affairs Advisor for Glaxo Group Research Ltd. in the U.K.
Kenneth P. Wolski, M.D., Vice President, Strategy and Policy, Merck, Sharp & Dohme Research Laboratories

Evaluating Cost Effectiveness: Future Requirements for Drug Approval and Reimbursement (09/10/1991)

David B. Evans, Ph.D., Health Economist, World Health Organization; former consultant to Australia’s Pharmaceutical Benefits Advisory Scheme on guidelines for cost effectiveness studies
Alan L. Hillman, M.D., M.B.A., Assistant Professor, University of Pennsylvania’s School of Medicine and the Wharton School; and Director, Center for Health Policy at the Leonard Davis Institute of Health Economics; lead author of recent article in The New England Journal of Medicine calling for ethical guidelines in the conduct of cost effectiveness studies
Louis A. Morris, Ph.D., Chief, Food and Drug Administration (FDA) Marketing Practices and Communications Branch; and Scholar-in-Residence, Center for Marketing and Public Policy Research, American University; currently serves part time as marketing and consumer research consultant at the Federal Trade Commission

Negotiated Drug Prices: Impact on the Private Sector (05/10/1991)

Roger Green, Principal, Roger Green & Associates; consultant for pharmaceutical clients; author of recent article forecasting how manufacturers will respond to new incentives coming from negotiated drug prices in Medicaid program
Daniel R. Hawkins, Jr., Director of Policy Analysis, National Association of Community Health Centers
James C. McAllister, M.S., Director of Pharmacy Services, Duke University Medical Center; and President, American Society of Hospital Pharmacists

Treatment Protocols and Outcome Measures: Future Directions (04/22/1991)

David M. Angaran, M.S., Professor and Department Chairman, and Associate Director of Pharmacy at Shands University of Florida College of Pharmacy
William T. McGivney, Ph.D., Director, Division of Health Care Technology, American Medical Association
Stephen C. Schoenbaum, M.D., M.P.H., Deputy Medical Director, Harvard Community Health Plan; and Associate Professor of Medicine, Harvard Medical School
summary

Cost Containment and Pharmaceutical Prices: Policy Goals and Consequences (03/27/1991)

Susan D. Horn, Ph.D., Professor, Department of Health Policy and Management, Johns Hopkins School of Hygiene and Public Health; and Director, Robert Wood Johnson Foundation Program for Faculty Fellowships in Health Care Finance
Andy Stergachis, Ph.D., Associate Professor of Pharmacy and Epidemiology; and Director of the Program in Pharmacoepidemiology and Drug Policy, University of Washington School of Pharmacy
Darwin E. Zaske, Pharm. D., Professor, University of Minnesota College of Pharmacy; and Director of Pharmaceutical Services, St. Paul-Ramsey Medical Center

The Role of the FDA in the 1990s (10/29/1990)

Arthur Hull Hayes, Jr., M.D., President and CEO, EM Pharmaceuticals Inc., former Assistant Surgeon General and former Commissioner of the U.S. Food and Drug Administration
Peter Barton Hutt, Esq., Partner, Covington & Burling, and former Chief Counsel for the U.S. Food and Drug Administration
Alexander MacKay Schmidt, M.D., Vice President and Director, Technology Advancement Center, University Hospital Consortium, Inc., and former Commissioner of the U.S. Food and Drug Administration

Long-Term Care: Problems and Opportunities (09/10/1990)

Peter P. Lamy, Ph.D., Sc.D., Professor, Geriatrics, Family Medicine, Epidemiology and Preventive Medicine, Assistant Dean of Geriatrics, and Director, Center for the Study of Pharmacy and Therapeutics for the Elderly, University of Maryland School of Medicine
Glenda J. Motta, R.N., President of GM Associates and past president of the International Association for Enterostomal Therapy
R. Tim Webster, Executive Director, American Society of Consultant Pharmacists
Michael D. Young, M.D., Ph.D., Corporate Director Worldwide Regulatory Affairs, R&D, The Procter & Gamble Company

National Health Funding: Effects on Innovation, Access and Quality (06/28/1990)

Jacques Krasny, Director and Managing Principal, Bogart Delafield Ferrier Inc.
Robert Neimeth, Vice President of Pfizer, Inc. and Executive Vice President of Pfizer International Inc.
Albert Wertheimer, Ph.D., Dean, Philadelphia College of Pharmacy and President, Academic Section of FIP (International Pharmaceutical Federation)

Rationing Health Care (05/21/1990)

Dave Kears, Director, Alameda County Health Care Services
The Honorable Rick Kotulski, Representative, Oregon State Legislature
Linda Schofield, Director, Connecticut Medical Care Administration

Formularies: Impacts on Health Care Costs and Pharmaceutical Innovation (04/17/1990)

Robert J. Newman, Ph.D., Professor and Partnership for Research Excellence Fellow, Department of Economics, Louisiana State University
Aaron Johnson, Commissioner, Georgia Department of Medical Assistance
Peter Singleton, M.D., Professor of Medicine, Meharry Medical College
Norrie Wilkins, M.D., Vice President, Pharmaceutical Management, Partners National Health Plans

The Affordability of Medicines (03/14/1990)

Robert Hills, Executive Director, National Customers and Policy, Merck Sharp & Dohme Division of Merck & Co., Inc.
Sanford Luger, R.P., Chief Pharmacy Consultant, New Jersey Medicaid Program
Stephen Schondelmeyer, Ph.D., Professor, Purdue University Pharmaceutical Economics Research Center

The Cost of Developing Medicines (12/11/1989)

Judy C. Lewent, Vice President and Treasurer, Merck & Co., Inc.
Hollings C. Renton, Executive Vice President and Chief Operating Officer, Cetus Corporation
W. Leigh Thompson, Jr., M.D., Ph.D., Group Vice President, Lilly Research Laboratories, Eli Lilly and Company; and Professor of Medicine, Indiana University School of Medicine

The Future of Marketing Medicines (11/15/1989)

David Lefkowitz, M.D., President, Physicians Pharmaceutical Network, and a practicing physician
Donald Rucker, Ph.D., Commissioner, Prescription Drug Payment Review Commission for the Office of Technology Assessment, economist, professor and Head, Department of Pharmacy Administration, University of Illinois at Chicago
Peter Seaver, Corporate Officer and Vice President, Worldwide Pharmaceutical Marketing at The Upjohn Company

Consumer Activism and the Drug Approval Process (09/22/1989)

Abbey Meyers, Founder and Executive Director, National Organization for Rare Disorders (NORD), member of the Board of Directors, National Health Council
Lloyd Ney, Founder, Patient Advocates for Advanced Cancer Treatments (PAACT), editor of Golden Years newsletter for senior citizens and Cancer Communication which informs readers of cancer research, legislation and therapies
Rebecca Smith, Study Coordinator, Community Research Initiative; board member, AIDS Treatment Registry; member of the Treatment and Data Committee for the organization AIDS Coalition to Unleash Power (ACT UP)

The Politics of Health Care in the 1990s (06/26/1989)

Glenna Crooks, Ph.D., Senior Director of Public Policy, Merck & Co., former Deputy Assistant Secretary for Health, Department of Health and Human Services
Robert Helms, Ph.D., Executive Director, American Pharmaceutical Institute, former Assistant Secretary for Planning and Evaluation and Deputy Assistant Secretary for Health Policy, Department of Health and Human Services
John Iglehart, editor and creator of the journal Health Affairs and national correspondent for The New England Journal of Medicine
Stephan Lawton, partner, Reed, Smith, Shaw & McClay and former Chief Counsel for the Subcommittee on Health and the Environment, Committee on Interstate and Foreign Commerce
John Middleton, President, Diversified Pharmaceutical Services, Inc. and former Vice President of Pharmacy Programs, United HealthCare Corporation

Controlling Health Care Costs While Ensuring Quality (04/14/1989)

Philip Caper, M.D., President, Codman Research Group, Inc.; Professor of Public Policy, Dartmouth Medical School; lecturer in Social Medicine and Health Policy at Harvard university’s School of Medicine; and former professional staff member of the Senate Labor and Human Resources Subcommittee on Health
Kathleen Lohr, Ph.D., Senior Professional Associate and Study Director, Institute of Medicine/National Academy of Sciences’ Division of Health Care Services and Council on Health Care Technology, and former health Policy analyst for The Rand Corporation
Maria Michnich, Dr.P.D., Associate Executive Vice President for Health Policy, American College of Cardiology; and former health staff member for Senator Robert Dole

Clinical Trials in the 1990s: New Methodologies for Drug Review (03/22/1989)

Larry Bruni, M.D., President, National Community Research Initiatives and physician who works with HIV positive patients
Judith K. Jones, M.D., Ph.D., President, The Degge Group, former Director of the FDA Division of Drug Experience and faculty member of the Georgetown University School of Medicine
Steven Kahane, M.D., M.S., Senior Vice President, Clinical Information Advantages, Inc. and former Director, Systems Development and Information Systems at Johns Hopkins University
Louis Lasagna, M.D., Chairman, President’s National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS and Director, Center for the Study of Drug Development at Tufts University
Robert Temple, M.D., Director, Office of Drug Evaluation I, Center for Drug Evaluation and Research of the Food and Drug Administration

The Future of the FDA Drug Approval Process (10/17/1988)

Gerald J. Mossinghoff, President, Pharmaceutical Manufacturers Association
Gary L. Neil, Ph.D., Divisional Vice President for Biotechnology and Basic Research Support for The Upjohn Company
William B. Shultz, J.D., Attorney for Public Citizens Litigation Group
Robert Temple, M.D., Director, Office of Drug Evaluation I, Center for Drug Evaluation and Research of the Food and Drug Administration

Economics of Genetic Testing, Disease Prevention and Treatment (09/14/1988)

Robert M. Greenstein, M.D., Professor of Pediatrics, University of Connecticut Health Center and Director, Division of Child and Family Studies
Lester Lave, Ph.D., James H. Higgins Professor of Economics, Carnegie-Mellon University and author
J. Howard Beales, III, Ph.D., Assistant Professor of Business Administration, George Washington University and former Chief, Human Resources and Housing Branch, Office of Information and Regulatory Affairs, Office of Management and Budget

Ethical Issues in Genetic Testing (06/21/1988)

Walter Truett Anderson, Ph.D., author and political scientist who has studied the politics of biotechnology and genetic resources
Neil Anton Holtzman, M.D., M.P.H., Professor of Pediatrics, Johns Hopkins University School of Medicine and Professor of Epidemiology in the School of Hygiene and Public Health
Philip R. Reilly, J.D., M.D., Director, Eunice Kennedy Shriver Center University Affiliated Program
summary

Animal Testing and New Model Systems (05/11/1988)

Alan M. Goldberg, Ph.D., Director, Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University
Emil Alvin Pfitzer, M.Sc., Sc.D., Assistant Vice President, Group Director, Department of Toxicology and Pathology, Hoffmann-La Roche Inc.
Henry Spira, Coordinator of animal rights coalitions has led efforts to abolish the LD-50 test and the Draize Rabbit Blinding Test

Alzheimer’s Disease and Pharmaceutical Development (03/31/1988)

John P. Blass, M.D., Ph.D., Professor, Department of Neurology and Medicine, Chief, Division of chronic and Degenerative Diseases, Cornell University’s Medical College, Staff Physician and Director, Dementia Research Service, Burke Rehabilitation Center, New York
Zaven S. Khachaturian, Ph.D., Associate Director, Office of Neuroscience and Neurobiology of Aging Program, NIA and Director, Office of Alzheimer’s Disease Research at NIH
Richard J. Wurtman, M.D., scientist, Harvard Medical School and Director, Clinical Research Center at Massachusetts Institute of Technology (MIT)

Generic Drugs and Bioequivalence (03/15/1988)

William Barr, Pharm. D., Ph.D., Professor and Chairman, Department of Pharmacy and Pharmaceutics, Virginia Commonwealth University’s Medical College
Anthony R. DiSanto, Ph.D., Vice President, Drug Delivery Research and Development, The Upjohn Company
Dee Fernsterer, President, Generic Pharmaceutical Industry Association

Product Liability and Pharmaceutical R&D (12/16/1987)

Zolla P. Horovitz, Ph.D., Vice President, Research Administration, Planning & Scientific Liaison at the Squibb Institute for Medical Research
Geoffrey R.W. Smith, J.D., Counsel, McCutchen, Doyle, Brown & Enersen and former Associate General Counsel, Pharmaceutical Manufacturers Association
Marianna S. Smith, J.D., Executive Director, Mannville Personal Injury Settlement Trust

AIDS Research: Vaccines and Treatment (10/14/1987)

David W. Barry, M.D., Vice President of Research and Head of the Department of Virology at the Burroughs Wellcome Co.
Anthony S. Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health
Michael E. Samuels, Dr. P.H., Assistant to the Surgeon General, U.S. Public Health Service

Pharmaceutical R&D and The Future of Geriatric Medicine (09/15/1987)

Darrell R. Abernethy, M.D., Ph.D., Director, Division of Clinical Pharmacology and Associate Professor of Medicine, Brown University
William B. Abrams, M.D., F.A.C.P., Executive Director for Scientific Development, Merck Sharp & Dohme Research Laboratories and Adjunct Professor of Medicine at Jefferson Medical College
Ronald W. Hart, Ph.D., Director, National Center for Toxicological Research of the Food and Drug Administration

Access to Pharmaceuticals in a Changing Health Care System (04/16/1987)

Willis B. Goldbeck, President of the Washington Business Group on Health and Founder and Consulting Editor of Business and Health
Vincent R. Gardner, President of Vince Gardner Associates and Associate Professor of Pharmacy Administration at the University of Texas at Austin
Michael A. Riddiough, President of the consulting firm Riddiough and Associates, pharmacist and public health expert

Biotechnology and the Regulation of Pharmaceuticals (03/18/1987)

Samuel Ackerman, M.D., Vice President for Medical and Regulatory Affairs with the Xoma Corp.
Ralph Christoffersen, Vice President for Biotechnology and Basic Research Support for the Upjohn Company
George Poste, M.D., Vice President and Director of R&D with SmithKline and French Laboratories Corporation
summary

International Trade, Competition, and the U.S. Pharmaceutical Industry (02/17/1987)

Tamara J. Erickson, Corporate Vice President and Manager of the Health Industries Management Section of Arthur D. Little, Inc.
Jay J. Kingham, Senior Vice President for International Affairs of the Pharmaceutical Manufacturers Association
Harvey E. Bayle, Jr., Assistant U.S. Trade Representative for Trade Policy and Analysis

The Future of the FDA (11/07/1985)

Mark Novitch, M.D., Corporate Vice President, The Upjohn Company and former Deputy Commissioner of the FDA
William W. Vodra, Associate, Arnold and Porter (in place of Eugene M. Pfeifer)
Peter H. Rheinstein, M.D., J.D., M.S., Director, Office of Drug Standards, Center for Drugs and Biologics, FDA

Nuclear Medicine and Low-Level Radioactive Waste (09/03/1985)

David M. Berick, Director, Nuclear Waste and Safety Project, Environment Policy Institute
Richard Guimond, Director, Criteria and Standards Division, Office of Radiation Programs of the Environmental Protection Agency
Henry N. Wagner, Jr., M.D., Professor of Medicine and Radiology, John Hopkins University School of Medicine and Professor of Environmental Health Sciences, John Hokins School of Hygiene and Public Health

The Prospects for Home Health Care (03/04/1985)

Joshua Wiener, Ph.D., Senior Fellow, Brookings Institution
Frederick R. Curtiss, Ph.D., R.Ph., Vice President of Reimbursement Services, HPI Health Care Services, Inc., and Adjunct Assistant Professor, School of Pharmacy, University of Southern California
Robert Harootyan, Project Director and Senior Analyst, Office of Technology Assessment

The Future of Diagnostic Testing (11/13/1984)

S. Raymond Gambino, M.D., Executive Vice President and Chief Medical Officer, MetPath, Inc. and Adjunct Professor of Pathology at Columbia University
Judith Wagner, Ph.D., Senior Analyst, U.S. Congress Office of Technology Assessment Health Program
Magdalena Usategui, Ph.D., Director, Roche Diagnostic Systems

The Future of Drugs and the Elderly (10/16/1984)

William B. Abrams, M.D., F.A.C.P., Executive Director for Scientific Development, Merck Sharp & Dohme Research Laboratories
Robert Temple, M.D., Director, Office of Drug Research and Review, Food and Drug Administration’s National Center for Drugs and Biologics
Julian Fisher, M.D., Executive Vice President, Computers in Medicine, Faculty, Harvard Medical School
summary

The Information Revolution in Health Care (07/30/1984)

James F. Fries, M.D., Associate Professor of Medicine, Stanford University
Robert L. Kane, M.D., Senior Researcher, Rand Corporation and Professor, U.C.L.A., School of Medicine
Marilyn Bergner, Ph.D., Professor of Health Services, University of Washington, Seattle
summary

The Future of Organ Transplantation (06/05/1984)

Gary E. Friedlaender, M.D., Yale University Orthopedic Surgeon and President of the American Council on Transplantation
Kenneth W. Sell, M.D., Ph.D., Scientific Director, National Institute of Allergy and Infectious Diseases
Samuel Gorovitz, Ph.D., University of Maryland

The Future of Cancer: Prevention, Treatment and Cure (02/02/1984)

Loretta M. Itri, M.D., Director of Clinical Oncology, Hoffman-La Roche
Michael Lerner, Ph.D., President, Commonweal
Edward Sondik, Ph.D., Chief of Operations, Research Branch, Division of Cancer Prevention and Control, National Cancer Institute

Cost Containment and Biomedical Research (11/10/1983)

Paul Ginsburg, Ph.D., Deputy Assistant Director for Income Security and Health, Congressional Budget Office
Helen L. Smits, M.D., Associate Professor of Medicine and Public Health, Yale School of Medicine
Burton A. Weisbrod, Ph.D., Professor of Economics, University of Wisconsin
summary

National Research Policy and Research into the Conditions of Aging (06/13/1983)

James F. Fries, M.D., Associate Professor of Medicine, Stanford University
Edward L. Schneider, M.D., Associate Director for Biomedical Research and Clinical Medicine, National Institute on Aging
R. Knight Steel, M.D., Director of the Gerontology Center, Boston University School of Medicine
summary

Research and Development in the Global Pharmaceutical Economy (04/11/1983)

Tamara J. Erickson, M.B.A., Manager of the Pharmaceutical Unit, Arthur D. Little, Inc.
Robert E. Stein, LL.B., Attorney at Law, President of Environmental Mediation International
William M. Wardell, M.D., Ph.D., Director of the Center for the Study of Drug Development, University of Rochester School of Medicine and Dentistry
summary

Brain Research and National Research Policy (03/15/1983)

Lee Goldman, Chief of Planning and Analysis, National Institute of Neurological & Communicative Disorders & Stroke (NIN/CDS)
Frederick Goodwin, M.D., Scientific Director, National Institute of Mental Health (NIMH)
Donald F. Klein, M.D., Director of Psychiatric Research at the New York State Psychiatric Institute

Pharmaceutical Research and Development Issues in the 98th Congress (02/09/1983)

Michael J. Hurley, J.D., Senior Associate, Booz-Allen & Hamilton Inc.
Stuart J. Land, J.D., Senior Partner, Arnold & Porter
Joseph Levitt, J. D., Associate Chief Counsel, Food and Drug Division, Office of the General Counsel for the Department of Health and Human Services

The Future of Biotechnology (12/15/1982)

Eric Drexler, S.M., Research Affiliate, MIT Space Systems Laboratory
Gretchen Kolsrud, Ph.D., Program Manager, Population and Genetics, Office of Technology Assessment
Kevin Ulmer, Ph.D., Director, Exploratory Research, Genex Corporation
summary

Animal Testing and New Drugs (11/16/1982)

A. M. Guarino, Ph.D., Review Scientist, New Drug Evaluation, National Center for Drugs and Biologics, FDA
Franklin M. Loew, D.V.M., Ph.D., Dean, Tufts University School of Veterinary Medicine
David Phelen, D.V.M., Director of Laboratory Animal Science, SmithKline and French Laboratories
Andrew N. Rowan, D.Phil., Associate Director, The Institute for the Study of Animal Problems of the Humane Society of America
summary

The Future of Coronary Heart Disease: Prevention, Treatment and Cure (09/26/1982)

Peter L. Frommer, M.D., Deputy Director, National Heart, Lung, and Blood Institute
Russell Jaffe, M.D., Ph.D., Consulting physician in health promotion
Robert B. Wallace, M.D., Professor and Chairman of the Department of Surgery, Georgetown University Medical Center
summary

The Future of Research Productivity (07/13/1982)

Joseph Perpich, M.D., J.D., Vice President for Corporate Planning and Administration
Denis Prager, Ph.D., Assistant Director for Life Sciences and Institutional Relations, Office of Science and Technology Policy, Executive Office of the President
Jacob C. Stucki, Ph.D., Vice President for Pharmaceutical Research, The Upjohn Company

Issues on Drug Testing (05/24/1982)

Norman Lavy, M.D., Vice President, Drug Regulatory Affairs, E.R. Squibb & Sons Inc.
Lawrence Miike, M.D., J.D., Senior Analyst Division of Health and Life Sciences, Congressional Office of Technology Assessment
Robert Temple, M.D., Acting Associate Director for New Drug Evaluation, Food and Drug Administration

The Recommendations of the Commission on the Federal Drug Approval Process (03/23/1982)

Barry M. Bloom, Ph.D., President, Pfizer Central Research
Louis Lasagna, M.D., Professor of Pharmacology and Toxicology and Professor of Medicine, University of Rochester School of Medicine
William W. Vodra, J.D. , Counsel, Arnold & Porter

Conference: Pharmaceuticals in the Year 2000 (03/03-04/1982)

Held at Project Hope’s Health Study Center

Welcome
Howard L. Binkley, Institute for Health Policy, Project HOPE

Policy Directions in the Current Health Care Context
William Walsh, M.D., President Project HOPE

The Task of the Conference
Clement Bezold, Ph.D., Director Institute for Alternative Futures

Images of the Year 2000
Harry Schwartz, Ph.D., Writer in Residence, College of Physicians and Surgeons, Columbia University

Health Conditions in the Year 2000
Peter G. Goldschmidt, M.D., Dr.P.H. Director, Health Services Research and Development Service, Veterans Administration

Research Breakthroughs by the Year 2000
Jane J. Stein, Contributing Editor, National Journal, author of Making Medical Choices

Government Policies and the Development of New Drugs
Edward Burger, M.D., Sc.D., Director, Institute for Health Policy Analysis, Georgetown University

The Pharmaceutical Industry in the Year 2000
Herbert J. Conrad , Vice President, Pharmaceuticals, Hoffmann-La Roche Inc.

Communications, Consumers & Pharmaceuticals
James S. Turner, J.D., Partner, Swankin & Turner

Panel Discussion
J. Richard Crout, M.D., Director of Bureau of Drugs, Food and Drug Administration
Jonah Shacknei , Counsel to the Chairman House Science and Technology Subcommittee on Natural Resources
Ronald F. Docksai, Ph.D. , Majority Health Director Senate Labor and Human Resources Committee
Henry Grabowski, Ph.D. , Professor of Economics Duke University

Frontiers of Drug Discovery (02/08/1982)

Katherine L. Bick, Ph.D., Acting Deputy Director of the National Institute of Neurological and Communicative Disorders and Stroke
Craig D. Burrell, M.D., Vice-President and Director of External Affairs, Sandoz, Inc.
Karen Gale, Ph.D., Pharmacology Department, Georgetown University Schools of Medicine and Dentistry

Achieving Nutrient Adequacy: Health and Policy Issues (09/22/1981)

Myron Brin, Ph.D., Director, Clinical Nutrition, Hoffmann-La Roche Inc.
Katherine L. Clancy, Ph.D., President, Society for Nutrition Education
Eleanor M. Pao, Ph.D., Nutritionist, Consumer Nutrition Center, U.S.D.A.

The Drug Regulatory Process: The Impact of Changing Procedures Before and After Market Approval (07/21/1981)

Marcia Greenberger, Managing Attorney, National Women’s Law Center
Ronald W. Hansen, Associate Director, Center for Research in Government Policy and Business, Graduate School of Management, University of Rochester
William W. Vodra, Associate, Arnold and Porter

Can Infectious Diseases Be Controlled: What Have We Learned from Antibiotics? (03/03/1981)

Harold Neu, M.D., Professor of Medicine and Pharmacology, Columbia University College of Physicians and Surgeons and Chief of the Division of Infectious Diseases, Columbia Presbyterian Medical Center
Claude Nash, Ph.D., Associate Director of Microbiology, Smith, Kline & French Laboratories
Richard Novick, M.D., Chairman, Department of Plasmid Biology, and Director of the Public Health Research Institute of the City of New York

Pharmaceutical R&D and Regulation: Background Overview for the 97th Congress (02/10/1981)

Peter Hutt, Partner, Covington & Burling
James Turner, Partner, Swankin & Turner

Orphan Drugs: Adjustments in the Approval Process? (12/02/1980)

Thomas Althuis, Ph.D., Senior Associate, Public Affairs Division, Pfizer
Irving Ladimer, J.D., S.J.D., Director, Health Services and Medical Malpractice Programs, Research Institute, American Arbitration Association
Barrett Scoville, M.D., Special Expert, Drug Development, Epilepsy Branch, Neurological Disorders Program, National Institute of Neurological and Communicative Disorders and Stroke

Drug Patents: The Impact of Restoring Patent Life Lost (11/12/1980)

Henry Grabowski, Ph.D., Professor of Economics, Duke University
Alan Louri, Ph.D., J.D., Vice President for Corporate Patents and Assistant General Counsel, SmithKline Corporation

Recombinant DNA, New Drugs, and Societal Choice (05/20/1980)

L. Patrick Gage, Ph.D., Director, Laboratory for Recombinant DNA Research, Hoffmann-La Roche, Inc.
Gretchen Kolsrud, Ph.D., Program Manager, Population and Genetics, Office of Technology Assessment
John Platt, Ph.D., Lecturer, Boston University School of Medicine

Nutrition Research and New Therapies (04/21/1980)

Myron Brin, Ph.D., Director, Department of Clinical Nutrition, Hoffmann-La Roche Inc.
Michael Lerner, Ph.D., President and Executive Director of Commonweal, a California health and educational resource center
Myron Winick, M.D., Director, Institute of Human Nutrition, Columbia University’s College of Physicians and Surgeons

Health Outcome Measures: Implications for Drug R & D (03/18/1980)

Peter G. Goldschmidt, M.D., M.P.H., Vice President of Policy Research
C. Norman Shealy, M.D., Ph.D., Director, Pain and Rehabilitation Center and President of the American Holistic Medical Association
Leonard Shifrin, Ph.D., Professor of Economics, College of William and Mary

The Environments for Optimal Research (02/26/1980)

J. Richard Crout, M.D., M.S., Director, Bureau of Drugs, U.S. Food and Drug Administration
Richard Faust, Ph.D., M.B.A., Director of Research Planning, Hoffmann-La Roche, Inc.
Henry Grabowski, Ph. D., Economist, Division of Economic Analysis, Health Care Financing Administration, Department of Health, Education and Welfare

Unmet Needs for Pharmaceutical Research and Development: Orphan Drugs (01/29/1980)

Seymour Cohen, Ph.D., Distinguished Professor, Department of Pharmacological Sciences, State University of New York
Clifford Joseph, M.D., Associate Medical Director, Hoffmann-La Roche
Barrett Scoville, M.D., Epilepsy Branch, Neurological Disorders Program of the National Institute of Neurological and Communicative Disorders and Strokes, National Institute of Health

Decision-Making Factors in Drug Regulation: Reevaluation of Drug Safety and Efficacy (11/06/1979)

Joseph T. Curti, M.C., Vice President and Medical Director, Pfizer Pharmaceuticals
James Turner, J.D., Swankin & Turner
William M. Wardell, M.D., Ph. D., Associate Professor of Pharmacology, Toxicology, and of Medicine and Director of the Center for the Study of Drug Development, University of Rochester School of Medicine and Dentistry

Recombinant DNA and New Drugs: Science, Policy, and Ethics (06/11/1979)

LeRoy Walters, Ph.D., Director, Georgetown University Center for Bioethics of the Kennedy Institutes of Health
Burke Zimmerman, Ph.D., Director, Division of Legislative Analysis, National Institutes of Health
Herbert Weissback, Ph.D., Associate Director, Roche Institute of Molecular Biology

The Impact of Regulation and Incentives for Pharmaceutical Research and Development (05/15/1979)

William S. Comanor, Ph.D., Director, Bureau of Economics, Federal Trade Commission
Leon I. Goldberg, Ph.D., M.D., Professor of Pharmacology and Medicine and Director of Clinical Pharmacology, University of Chicago
Hubert C. Peltier, M.D., Senior Vice President of Research, Merck, Sharp, and Dohme Research Laboratories

The National Center for Clinical Pharmacology: Policy Questions and Long Term Consequences (03/19/1979)

John Burns, Ph.D., Vice President, Research, Hoffmann-La Roche
Marcia Greenberger, J.D., Director of the Women’s Rights Project, Center for Law and Social Policy
John Oates, M.D., Professor of Medicine and Pharmacology and Director of Clinical Pharmacology, Vanderbilt University School of Medicine

The Impact of National Health Insurance on Pharmaceutical Research and Development (11/13/1978)

Peter Goldschmidt, M.D., M.P.H., M.B.A., Policy Research, Inc.
Michael Riddiough, Pharm.D., M.P.H., Senior Analyst, Health Program, Office of Technology Assessment
John Virts, Ph.D., Corporate Economist, Eli Lilly & Co.

The Future of Pharmaceuticals: Breakthrough Possibilities, Development Constraints, and Policy Questions (09/18/1978)

Jerome E. Schnee, Ph.D., Graduate School of Business, Rutgers University
Frank Standaert, M.D., Department of Pharmacology, Georgetown University School of Medicine
James Turner, J.D., Swankin & Turner